Skip to main content
Equibles
VNDA logo

VNDA · Vanda Pharmaceuticals Inc. · Metrics

Track VNDA — free

Use VNDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VNDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.09 +0.05 (+0.99%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$307.76M
Shares
60.46M

VNDA metrics

68 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.09
Market cap
$307.76M

Price action

20 metrics
Price change (1W)
-5.6%
Price change (30D)
+0.2%
Price change (3M)
-17.4%
Price change (6M)
-45.7%
Price change (YTD)
-42.9%
Price change (1Y)
+12.5%
Trailing year
Price change (5Y)
-68.9%
52-week high
$9.56
52-week low
$4.32
Change from 52-week high
-47.3%
Change from 52-week low
+16.7%
Annualized volatility
82.0%
Annualized volatility (3M)
40.7%
Beta
0.8
RSI (14D)
40.2
Price vs SMA 50
-7.6%
Price vs SMA 200
-23.4%
Avg volume (3M)
910,808
Relative volume
1.1
Average dollar volume
$5.04M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
60.46M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.4×
reciprocal yield 69.8%
P / book
1.4
reciprocal yield 71.2%
FCF yield
-46.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-88.9%

Historical valuation

8 metrics
P / E historical average (3Y)
42.5×
reciprocal yield 2.4%
P / E historical average (5Y)
35.2×
reciprocal yield 2.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-86.1%
Trailing 12 months
Net margin
-127.4%
Gross profit (TTM)
$223.33M
Operating profit (TTM)
−$185.67M
Net income (TTM)
−$274.85M
Trailing 12 months
Diluted EPS (TTM)
$-4.64
FCF margin
-66.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.54

Growth

11 metrics
Revenue growth YoY
-3.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$215.72M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
-5.3%
Revenue CAGR (5Y)
-2.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-124.8%
Return on assets
-66.6%
Debt / equity
—
Current ratio
1.6
EBITDA (TTM)
$44.95M
Free cash flow (TTM)
−$143.00M
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
-1.0
Return on invested capital
—
Trailing 12 months
Net cash
$55.88M
Latest balance sheet
Cash & equivalents
$55.88M
Total assets
$412.47M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$142.33M
Capital expenditures (TTM)
$674,000
R&D (TTM)
$116.96M
SG&A (TTM)
$263.45M
Stock compensation (TTM)
$9.07M
R&D / revenue
54.2%
Stock compensation / revenue
4.2%

Ownership (13F)

3 metrics
13F filers
172
13F filer change QoQ
-1
Institutional ownership
82.5%

Short interest

3 metrics
Short interest
12.7%
Latest settlement · 9.9 days to cover
Days to cover
9.9d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1347178 CUSIP 921659108 13F (30d) 87 filings 87 filers Visit website Investor relations